Watchdog Bans First Ads for Oral Weight Loss Meds: Public Safety Alert!
Watchdog Bans First Ads for Oral Weight Loss Meds: Public Safety Alert!
The Advertising Standards Authority (ASA) has banned the first ads for oral weight loss medicines, citing promotions of unlicensed and prescription-only products. Regulators are cracking down to protect public health fro
In a significant move to safeguard public health, the Advertising Standards Authority (ASA) has issued bans on the first advertisements for oral weight loss medicines. The watchdog's rulings targeted several companies for promoting unlicensed and prescription-only products directly to the public, often through social media and their websites.
The ASA found that Simple Online Pharmacy and Pharmacy Online were among those advertising oral GLP-1 treatments, even inviting potential customers to join waiting lists or pre-order treatments. Crucially, at the time of some of these ads, these medicines had not yet received full marketing authorisation in the UK, making their promotion illegal.
For instance, an ad from Simple Online Pharmacy on June 1st promoted oral GLP-1 treatments before the first such medicine was licensed as prescription-only on June 11th.
Advertising rules are clear: medicines must be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) before they can be promoted. Furthermore, once a medicine is classified as 'prescription-only,' it cannot be advertised directly to the public. The ASA's investigation highlighted how Pharmacy Online promoted the oral Wegovy tablet after it became prescription-only, with ads including website pop-ups inviting pre-orders.
Beyond these two, the watchdog also issued three further rulings against MedExpress, Juniper, and the Care Pharmacy for similarly promoting prescription-only medicines to the public. Even without explicitly naming products, the ASA's research showed that people could still infer they were referring to weight-loss medication, which falls under the same advertising restrictions.
The ASA stressed the importance of considering the overall impression an ad gives.
Catherine Drewett, investigations manager at the ASA, commented on the challenges posed by new treatment options, stating, "These first rulings make clear that these oral medicines, like prescription-only injections, cannot be advertised to the public.
These are powerful medicines so it's important that ads don't encourage people to seek treatment in ways that could put them at risk."
Julian Beach, executive director of healthcare, quality and access at the MHRA, echoed this sentiment, welcoming the ASA's swift action. He emphasised that stimulating consumer demand for new prescription medicines is not permitted and that such advertising breaches, especially for weight loss medicines, are taken very seriously due to the potential risks to patient safety.
The MHRA works closely with regulators like the ASA and the General Pharmaceutical Council (GPhC) to ensure compliance and protect the public.
Regulators have warned that weight loss prescription medicines are potent treatments that require supervision from a qualified medical professional.
Irresponsible or illegal advertising of these products can endanger individuals, making this a high-priority area for ongoing monitoring and enforcement.
